It's frankly more difficult to find overvalued health care stocks today than undervalued ones, assuming that the market can transition through this dry spell and that procedure volumes pick up with an eventual economic recovery. Given that Hologic (Nasdaq:HOLX) serves markets largely seen as mature, many investors question whether the company can grow fast enough to be worthwhile. Although that is a legitimate concern, investors have become pessimistic to a point where even modest growth could lead to a strong rebound in the stock.

Investopedia Markets: Explore the best one-stop source for financial news, quotes and insights.

A Respectable End to the Year
Hologic's business is a combination of solid higher-growth businesses and some smaller, more sluggish operations. Overall growth rose 9% this quarter, with breast health and diagnostics up 11 and 12% respectively, while the surgical and skeletal health businesses grew 1 and 2%. Given that this is still a pretty unhealthy market for capital equipment and doctor office visits, these are pretty solid results. (For related reading on heath care, see How To Avoid Medical Debt.)

On the profitability side, Hologic did OK, but less well. There are a couple of different ways to calculate Hologic's gross margin (depending on whether an investor wants to factor in all of the amortization), but the company posted a half-point (or better) improvement in gross margin either way. Further down the line, adjusted operating income rose 7% as the company swallowed some higher acquisition integration costs and costs tied to a direct marketing campaign for its NovaSure product.

Tomo Starting Strong
Hologic has long been counting on advanced technology (tomosynthesis) to help it stand out better from General Electric (NYSE:GE) and Siemens (NYSE:SI) in the mammography market. So far, it seems to be going well, as the company is seeing surprisingly strong acceptance. Better still, reimbursement for procedures using the new equipment has been favorable, though any investor familiar with service companies like Lincare (Nasdaq:LNCR) or even other device companies like Stryker (NYSE:SYK) can attest to how reimbursement can change quickly.

Can Hologic Maintain Diagnostics Growth?
It was encouraging to see 16% volume growth in the company's ThinPrep diagnostics product. That said, this is a market that is getting more and more crowded. Abbott (NYSE:ABT), Becton Dickinson (NYSE:BDX), Qiagen (Nasdaq:QGEN) and Siemens all want a piece of this lucrative recurrent market, and Gen-Probe (Nasdaq:GPRO) is coming out with a new product of its own. Making matters worse, there's conflicting guidance on just how often women need certain routine tests and confusion could stall market growth.

Moving Abroad
To management's credit, Hologic has been positioning itself for more overseas growth. It is certainly true that there are still many women in developed countries that do not get routine mammograms or gynecological tests, but that pales in comparison to the under-penetration of emerging markets (where, in many cases, some people never see a doctor for routine care). As countries like China, India, and Brazil develop and improve their health care systems, this should become a sizable growth opportunity.

The Bottom Line
There's plenty already out there on the poor state of routine health care procedure volumes, and it affects both Hologic and its competitors like Johnson & Johnson (NYSE:JNJ), Bard (NYSE:BCR) and Abbott. It is not at all likely to be a permanent situation, though. If the economy improves and unemployment goes back to a more historically normal level, it stands to reason that health care utilization will rebound. In the meantime, Hologic has a growing overseas business and the opportunity to do more deals in the meantime.

If Hologic can deliver mid-single-digit revenue growth and gradual margin improvement, the stock is under-priced to a meaningful degree. The Street would no doubt like to see more obvious growth market opportunities for Hologic, but patient investors could well be rewarded with the as-is business at this women's health specialist. (For related reading, see Investing In The Healthcare Sector.)

Use the Investopedia Stock Simulator to trade the stocks mentioned in this stock analysis, risk free!

At the time of writing, Stephen Simpson did not own shares in any of the companies mentioned in this article.

Related Articles
  1. Stock Analysis

    Will J.C. Penney Come Back in 2016? (JCP)

    J.C. Penney is without a doubt turning itself around, but that doesn't guarantee the stock will respond immediately.
  2. Stock Analysis

    Allstate: How Being Boring Earns it Billions (ALL)

    A summary of what Allstate Insurance sells and whom it sells it to including recent mergers and acquisitions that have helped boost its bottom line.
  3. Options & Futures

    Cyclical Versus Non-Cyclical Stocks

    Investing during an economic downturn simply means changing your focus. Discover the benefits of defensive stocks.
  4. Investing Basics

    How to Deduct Your Stock Losses

    Held onto a stock for too long? Selling at a loss is never ideal, but it is possible to minimize the damage. Here's how.
  5. Economics

    Is Wall Street Living in Denial?

    Will remaining calm and staying long present significant risks to your investment health?
  6. Stock Analysis

    When Will Dick's Sporting Goods Bounce Back? (DKS)

    Is DKS a bargain here?
  7. Investing News

    How AT&T Evolved into a Mobile Phone Giant

    A third of Americans use an AT&T mobile phone. How did it evolve from a state-sponsored monopoly, though antitrust and a technological revolution?
  8. Stock Analysis

    Home Depot: Can its Shares Continue Climbing?

    Home Depot has outperformed the market by a wide margin in the last 12 months. Is this sustainable?
  9. Stock Analysis

    Yelp: Can it Regain its Losses in 2016? (YELP)

    Yelp investors have had reason to be happy recently. Will the good spirits last?
  10. Stock Analysis

    Is Walmart's Rally Sustainable? (WMT)

    Walmart is enjoying a short-term rally. Is it sustainable? Is Amazon still a better bet?
  1. How do dividends affect retained earnings?

    When a company issues a cash dividend to its shareholders, the retained earnings listed on the balance sheet are reduced ... Read Full Answer >>
  2. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  3. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  4. How does additional paid in capital affect retained earnings?

    Both additional paid-in capital and retained earnings are entries under the shareholders' equity section of a company's balance ... Read Full Answer >>
  5. What types of capital are not considered share capital?

    The money a business uses to fund operations or growth is called capital, and there are a number of capital sources available. ... Read Full Answer >>
  6. What is the difference between issued share capital and subscribed share capital?

    The difference between subscribed share capital and issued share capital is the former relates to the amount of stock for ... Read Full Answer >>

You May Also Like

Trading Center